Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials

被引:42
作者
Korkmaz, Taner [1 ]
Seber, Selcuk [2 ]
Basaran, Gul [1 ]
机构
[1] Acibadem Univ Hosp, Istanbul, Turkey
[2] Namik Kemal Univ Hosp, Tekirdag, Turkey
关键词
Ovarian cancer; Maintenance treatment; Targeted therapy; RANDOMIZED PHASE-III; PEGYLATED LIPOSOMAL DOXORUBICIN; ENDOTHELIAL GROWTH-FACTOR; PRIMARY PERITONEAL; FALLOPIAN-TUBE; PLATINUM; CHEMOTHERAPY; BEVACIZUMAB; CARCINOMA; OLAPARIB;
D O I
10.1016/j.critrevonc.2015.10.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Late and recurrent stage ovarian cancer has a high mortality and low response rate to therapy beyond first line treatment. Although first line platinum/taxane based regimens have a satisfactory response rate eventually in most cases disease recurrence is common and second-line treatments are not curative. Delaying progression or recurrence is the main goal of current ongoing clinical studies by means of establishing an effective maintenance regimen with acceptable toxicity profile. Clearly, the persistence of dormant and drug-resistant cells after front-line treatments results in the inability to cure the disease. Over the past several years, the idea of prolongation of therapy for ovarian cancer has garnered clinical attention and academic debate. As a result of a greater understanding of the molecular pathways involved in carcinogenesis and tumor growth, a large number of potential therapeutic targets have been identified and drugs to block receptors, ligands or pathways are being developed. Currently, numerous clinical trials with targeted agents have just been completed or are ongoing involving patients achieving a complete or durable response after first-line and beyond the first line chemotherapy in order to evaluate the efficacy of different therapeutic approaches in terms of progression-free survival and overall survival. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:180 / 188
页数:9
相关论文
共 50 条
[41]   Overall survival and post-progression survival are potent endpoint in phase III trials of second/third-line chemotherapy for advanced or recurrent epithelial ovarian cancer [J].
Shimokawa, Mototsugu ;
Kogawa, Takahiro ;
Shimada, Takako ;
Saito, Toshiaki ;
Kumagai, Hozumi ;
Ohki, Masafumi ;
Kaku, Tsunehisa .
JOURNAL OF CANCER, 2018, 9 (05) :872-879
[42]   Current First-line Therapy for Ovarian Cancer: A Comprehensive Review [J].
Pierce, Stuart R. ;
Clark, Leslie H. .
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) :650-657
[43]   The challenges and opportunities in ovarian cancer relapse-the role of second and third-line chemotherapy: literature review [J].
Greening, Semini ;
Sood, Nikita ;
Nicum, Shibani .
GYNECOLOGY AND PELVIC MEDICINE, 2022, 5
[44]   Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer [J].
Strickler, John H. ;
Hurwitz, Herbert I. .
ONCOLOGIST, 2012, 17 (04) :513-524
[45]   Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer [J].
Goh, Jeffrey C. H. ;
Gourley, Charlie ;
Tan, David S. P. ;
Nogueira-Rodrigues, Angelica ;
Elghazaly, Hesham ;
Pierre, Marc Edy ;
Giornelli, Gonzalo ;
Kim, Byoung-Gie ;
Morales-Vasquez, Flavia ;
Tyulyandina, Alexandra .
GYNECOLOGIC ONCOLOGY REPORTS, 2022, 42
[46]   First-line molecular therapies in the treatment of metastatic colorectal cancer - a literature-based review of phases II and III trials [J].
Vogel, Arndt ;
Kirstein, Martha M. .
INNOVATIVE SURGICAL SCIENCES, 2018, 3 (02) :127-138
[47]   First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions [J].
Antonio González-Martín ;
Luisa Sánchez-Lorenzo ;
Raquel Bratos ;
Raúl Márquez ;
Luis Chiva .
Drugs, 2014, 74 :879-889
[48]   Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions [J].
Vetter, Monica Hagan ;
Hays, John L. .
CLINICAL THERAPEUTICS, 2018, 40 (03) :361-371
[49]   Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer [J].
Lawrie, Theresa A. ;
Rabbie, Roy ;
Thoma, Clemens ;
Morrison, Jo .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10)
[50]   Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis [J].
Vertechy, Laura ;
Ergasti, Raffaella ;
Chiamenti, Cristina ;
Arrigo, Davide ;
Ruscito, Ilary ;
Rizzi, Alessandra ;
Boccia, Serena Maria ;
Sassu, Carolina Maria ;
Scambia, Giovanni ;
Fagotti, Anna ;
Marchetti, Claudia .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025,